Drug-susceptible tuberculosis
Pulmonary or extrapulmonary tuberculosis with preserved M. tuberculosis susceptibility to isoniazid, rifampicin, ethambutol, and pyrazinamide. The standard regimen is a 2-month intensive phase (4 drugs) followed by a 4-month continuation phase (isoniazid + rifampicin).
ICD-10 A152 drugs
Also known as: Drug-susceptible TB, Pansusceptible TB
Drugs used for this condition
- ARifabutinSecond line · Antitubercular, rifamycin derivativeRifabutin is second-line antitubercular in standard 4-drug regimen (replacing rifampicin) in HIV-positive patients on ART or transplant recipients. WHO 2024 recommends rifabutin when rifampicin causes unacceptable drops in co-administered drug levels.
- ARifampicinFirst line · Antituberculous antibioticRifampicin is a mandatory component of the standard regimen for drug-susceptible tuberculosis. WHO 2022 and IDSA/CDC/ATS 2016 recommend a 6-month regimen: 2-month intensive phase with isoniazid + rifampicin + pyrazinamide + ethambutol (HRZE), and 4-month continuation phase with isoniazid + rifampicin (HR). Rifampicin dose is 10 mg/kg/day (usually 600 mg). The alternative 4-month rifapentine-based regimen (HPMZ) is suitable for selected patients per WHO 2022.
How to read tiers A–F
Evidence tiers belong to the drug-indication pair, not to the drug as a whole: the same substance can be A for one condition and F for another.
- AStrong evidence – first or second line in international guidelines
- BRecommended in selected cases
- CStudy data contradict each other
- DBenefit not proven, no documented harm
- FDocumented harm, or risk without benefit